IXC invex therapeutics ltd

Ann: Invex Granted Key European Patent for Exenatide, page-45

  1. 17,065 Posts.
    lightbulb Created with Sketch. 1365
    PAR - 416 mill MC
    RAC - 423 mill MC
    OPT - 456 mill MC
    NEU - 260 mill MC

    IXC - 49 mill MC

    Even if it got to NEU say, thats 5 x from here or $3.50 share price. Get real punters, this is the biggest gift on the ASX. Wait in 2 years time when we will say to ourselves, I cant believe how obvious this was, wish I bought more.

    Dr Duthy also noted that comparable companies on the ASX which are either repurposing approved therapies, developing orphan drugs, or developing ophthalmology therapies, such asParadigm Biopharmaceuticals (ASX: PAR),Opthea (ASX: OPT),Race Oncology (ASX: RAC)orNeuren Pharmaceuticals (ASX: NEU), are priced significantly higher despite similar stages of development.

    Patience people patience
    Last edited by italabria: 18/08/21
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
13.0¢
Change
0.020(18.2%)
Mkt cap ! $9.77M
Open High Low Value Volume
11.0¢ 13.0¢ 11.0¢ $3.651K 28.89K

Buyers (Bids)

No. Vol. Price($)
1 12000 10.5¢
 

Sellers (Offers)

Price($) Vol. No.
12.0¢ 25000 1
View Market Depth
Last trade - 10.45am 17/09/2025 (20 minute delay) ?
IXC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.